1. Home
  2. CBL vs SYRE Comparison

CBL vs SYRE Comparison

Compare CBL & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBL
  • SYRE
  • Stock Information
  • Founded
  • CBL 1978
  • SYRE 2013
  • Country
  • CBL United States
  • SYRE United States
  • Employees
  • CBL N/A
  • SYRE N/A
  • Industry
  • CBL Real Estate Investment Trusts
  • SYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • CBL Real Estate
  • SYRE Health Care
  • Exchange
  • CBL Nasdaq
  • SYRE Nasdaq
  • Market Cap
  • CBL 898.9M
  • SYRE 1.1B
  • IPO Year
  • CBL 1993
  • SYRE 2016
  • Fundamental
  • Price
  • CBL $29.67
  • SYRE $23.56
  • Analyst Decision
  • CBL
  • SYRE Strong Buy
  • Analyst Count
  • CBL 0
  • SYRE 6
  • Target Price
  • CBL N/A
  • SYRE $57.60
  • AVG Volume (30 Days)
  • CBL 104.5K
  • SYRE 1.3M
  • Earning Date
  • CBL 11-10-2025
  • SYRE 11-06-2025
  • Dividend Yield
  • CBL 6.08%
  • SYRE N/A
  • EPS Growth
  • CBL 128.05
  • SYRE N/A
  • EPS
  • CBL 2.10
  • SYRE N/A
  • Revenue
  • CBL $539,452,000.00
  • SYRE N/A
  • Revenue This Year
  • CBL N/A
  • SYRE N/A
  • Revenue Next Year
  • CBL N/A
  • SYRE N/A
  • P/E Ratio
  • CBL $14.13
  • SYRE N/A
  • Revenue Growth
  • CBL 2.20
  • SYRE N/A
  • 52 Week Low
  • CBL $21.10
  • SYRE $10.91
  • 52 Week High
  • CBL $33.54
  • SYRE $40.26
  • Technical
  • Relative Strength Index (RSI)
  • CBL 49.67
  • SYRE 70.08
  • Support Level
  • CBL $28.86
  • SYRE $21.88
  • Resistance Level
  • CBL $29.90
  • SYRE $24.02
  • Average True Range (ATR)
  • CBL 0.58
  • SYRE 1.62
  • MACD
  • CBL 0.10
  • SYRE 0.32
  • Stochastic Oscillator
  • CBL 87.56
  • SYRE 93.11

About CBL CBL & Associates Properties Inc.

CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: